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INTRODUCTION
This century has witnessed several spectacular developments in 
the field of  pharmaceutical  sciences especially  in the drug delivery 
systems. 1Throughout the past two decades, the transdermal patch has 
become a proven technology that offers a variety of significant clinical 
benefits over other dosage forms.
2Transdermal  drug  delivery  systems  have  been  developed, 
aiming  to  achieve  the  objective  of  systemic  medication  through 
topical  application  to  the  intact  skin.  Because  transdermal  drug 
delivery offers controlled release of drug into the patient, it enables a 
steady blood level profile, resulting in reduced systemic side effects 
and  sometimes,  improved  efficacy  over  other  dosage  forms.  In 
addition transdermal  patches  are  user  friendly,  convenient,  painless 
and  offer  multiday  dosing,  it  is  generally  accepted  that  they  offer 
improved patient compliance.
“Transdermal  drug  delivery  is  defined  as  self  contained,  
discrete dosage form which when applied to the intact skin, deliver  
the  drug  through  the  skin  at  controlled  rate  to  the  systemic  
circulation”.
Transdermal  drug  delivery  system  is  a  means  by  which  a 
pharmacologically  active  moiety  may  be  continuously  delivered 
systemically  in  an  efficient,  reliable  and  safe  manner.  They  are 
capable  of  better  performance  than  conventional  delivery  by 
monitoring the concentration, location and duration of drug action.
Transdermal product has been in a significant upward trend and 
that is likely to continue for the foreseeable future. 3The first adhesive 
transdermal delivery system (TDDS) patch was approved by the Food 
and  Drug  Administration  in  1979  (scopolamine  patch  for  motion 
sickness).  Nitroglycerine  patches  were  approved  in  1981. 
4Transdermal  clonidine  was  approved  by  the  US  Food  and  Drug 
Administration 1984 for the treatment mild-to-moderate hypertension 
alone or in combination with diuretic. This method of delivery became 
widely recognized when nicotine patches for smoking cessation were 
introduced in 1991. 
Over the past two decades, more than 35 transdermal products 
have been approved generating sales of $3.2billion in 2002, which is 
predicted  to  rise  to  $4.5billion  in  2008.  This  rapid  increase  in  the 
market value has lead to transdermal drug delivery becoming one of 
the fastest sectors within pharmaceutical industry.
Conceptual Origin of TDDS5
The  potential  of  using  intact  skin  as  the  part  of  drug 
administration has been recognized for several decades, as evidenced 
by  development  of  medicated  plasters.  Transdermal  delivery  of 
medications  was  foreshadowed in  earlier  era  by  the  use  of  certain 
plasters and ointments.
Historically  medicated  plaster  can  be  viewed  as  the  first 
development  of  transdermal  drug  delivery.  It  is  designed  to  bring 
medication into close contact with skin so that drug can be delivered 
transdermally.
The use of medicated plasters could be traced several 100 years 
back  in  ancient  China.  The  medicated  plaster  has  also  been  very 
popular  in  Japan  and  many  are  available  as  OTC  pharmaceutical 
dosage  forms,  commonly  called  cataplasms.  In  United  States  the 
following  three  medicated  plasters  have  been  listed  in  official 
compendia namely belladonna plaster,  mustard plaster  and salicylic 
acid plaster. These plasters are rather simple in formulation and were 
developed mainly for local medication.
Developments in Transdermal Drug Delivery
The skin was thought to be an impervious barrier. At the turn of 
the century, during World War II, munitions workers experienced less 
angina attacks while working with Nitroglycerin. This has challenged 
the traditional belief that the skin is a perfect barrier and also triggered 
intensive  research  activities  to  study  the  feasibility  of  transdermal 
drug  delivery  for  systemic  medications.  Several  Transdermal  Drug 
Delivery Systems (TDDS) have been developed recently, with the aim 
of  accomplishing  the  objective  of  systemic  medication  through the 
transdermally controlled delivery of pharmaceuticals. The potential of 
TDDS  was  first  demonstrated  by  the  successful  development  of 
scopolamine releasing TDDS (Transdermal scop system/ Ciba) for 72 
hrs prophylaxis or treatment of motion sickness and nausea then by 
marketing success of  this TDDS. Several  products  were introduced 
immediately,  some  of  them are  Nitroglycerin-  releasing  TDDS for 
once-a-day medication of angina pectoris, clonidine- releasing TDDS 
for weekly therapy of hypertension and Estradiol- releasing TDDS for 
twice -a- week treatment for menopausal syndrome.
In addition to the currently marketed formulations, new drugs 
are  being  formulated  using  transdermal  systems  because  of  the 
inherent advantage of administration by this route. Buslpar, an anti- 
anxiety  agent  and the combination  of  Mecamylamine,  for  smoking 
cessation  therapy are  being developed for  TDDS and are  currently 
undergoing phase-III clinical trials.
Even  it  has  been  said  that  TDDS can  be  given  to  newborn 
infants, IV therapy to infants is difficult and painful. Absorption of the 
drugs by oral therapy may be erratic to infants. The skin of preterm 
infants is  more permeable to drugs.  As dose requirements are very 
small  in infants,  the permeability  is  high and TDDS may be more 
useful. However lot of precautions and care must be taken during the 
administration of TDDS to infants and it is also said that transdermal 
formulations containing antibiotic combination gives better treatment 
for second-degree wounds.
Potential Benefits of TDDS6
 Steady state infusion of drug over an extended period of time.
 TDDS can decrease the therapeutic failure of many drugs and 
avoids problem associated with the drug like first pass effect, 
decomposition of drugs and GI irritations.
 Improved  patient  compliance  due  to  simplified  medication 
regimen.
 It permits continuous drug administration and the use of drug 
with short biological half-life.
 Multi day therapy with single application.
 Self medication is possible.
 Minimise inter and intra patient variation.
 It avoids the risks and inconvenience of IV therapy.
 Termination of medication is possible at any time if needed by 
simply removing the TDDS from skin surface.
 Provides predictable extended duration of activity.
Limitations of TDDS7
 TDDS cannot be used for all drugs.
 The drug must have desirable physical chemical properties for 
penetration through stratum corneum.
 Skin irritation or contact dermatitis.
 Only low dose drug can be used.
 Variable  intra  and  inter  individual  percutaneous  absorption 
efficiency.
 High cost.
Skin Structure and Barrier Properties5
Human  skin  is  uniquely  engineered  organ  that  permits 
terrestrial life by regulating heat and water loss from the body whilst 
preventing the entry of noxious chemicals or micro organisms. It is the 
largest organ of the human body providing around 10% of the body 
mass of an average person and it  covers an average area of 1.7m2. 
Whilst such a large and easily accessible organ apparently offers ideal 
and multiple sites to administer therapeutic agents for both local and 
systemic  actions.  Human  skin  is  a  highly  efficient  self  repairing 
barrier designed to keep “inside in and outside out”.
For the purpose of TDD the structure and function of human 
skin is categorized into four main layers. 
Fig 1 
The structural relationship among stratum corneum, viable 
epidermis, and the capillary network at the dermoepidermal 
junction
1. The outer most layer of tissue (a nonviable epidermal layer), the 
stratum corneum.
2. The viable epidermis.
3. The overlying dermis.
4. The innermost subcutaneous fatty layer, hypodermis
The Stratum Corneum
It is horny layer which is rate limiting barrier that controls the 
inward and outward movement of chemical substances.
The  stratum  corneum  typically  comprises  10-15  cell  layers. 
This membrane consisting of dead, nucleate cells embedded in lipid 
matrix is essential for controlling the percutaneous absorption of most 
drugs and chemicals.  The barrier nature of the horny layer depends 
critically on its constituents, 75 - 80 % proteins, 5-15% lipids and 5-
10% unidentified materials on a dry weight basis. The protein fraction 
predominantly comprises of keratin filaments which are cross linked 
by inter molecular disulfide bridges.
The Viable Epidermis
The  epidermis  is  a  layer  which  comprises  of  the  rapidly 
dividing basal cells. Migration of active epithelial basal cells towards 
the skin surface forms, thin stratified and extremely resilient layer at 
the skin surface called stratum corneum. Below this layer are the other 
layers of epidermis that is stratum lucidum, stratum granulose, stratum 
spinosum and stratum basale or germinativum.
The Dermis
The dermis  is  3-5mm thick  and is  composed  of  a  matrix  of 
connective  tissue  in  which predominant  bundles  of  collagen  fibrils 
interlace  with  elastic  tissue  and  sparse  reticular  fibers.  The dermis 
encloses  cutaneous appendages  and is  penetrated by blood vessels, 
lymphatic and nerves
In  terms  of  TDDS this  layer  is  viewed as  essentially  gelled 
water and thus provides a minimal barrier to the delivery of most polar 
drugs,  although  dermal  barrier  may  be  significant  when  delivering 
highly lipophilic molecules.
The Innermost Subcutaneous Fatty Layer
The fatty layer bridges between the overlying dermis and the 
underlying body constituents. This layer of adipose tissue principally 
serves to insulate the body and to provide mechanical protection. It 
can also provide a readily available supply of high energy molecules 
while the principal blood vessel nerves are carried to skin in this layer.
FUNDAMENTALS OF SKIN PERMEATION
Transdermal permeation is depended on three steps: 
 Sorption of stratum corneum
 Penetration of drug through viable epidermis.
 Uptake of drug by the capillary network in the dermis.
The rate of  permeation,  dQ/dt  across  the skin tissues  can be 
expressed mathematically by the following relationship
dQ
dt
=P s Cd−C r 
Where Cd and Cr, respectively are the concentration of skin penetrant 
in  the  donor  compartment  e.g.  the  concentration  of  drug  on  the 
stratum corneum surface as delivered from a TDD system, and in the 
receptor  phase,  e.g.  systemic  circulation;  and  Ps  is  the  overall 
permeability  coefficient  of  the  skin  tissues  to  the  penetrant  and  is 
defined by
Ps=
K s /d D ss
hs
Where Ks/d is the partition coefficient, for the interfacial partitioning of 
a  penetrant  molecule,  from  the  solution  medium  or  a  transdermal 
therapeutic  system  on  to  a  stratum  corneum;Dss  is  the  apparent 
diffusivity  for  the  steady  state  diffusion  of  the  penetrant  molecule 
through  the  skin  tissues  for  penetration  ;  and  hs   is   the  overall 
thickness of the skin tissues for penetration.
Fig 2
Multilayer skin model showing the sequence of 
transdermal permeation of drug
This suggests that to achieve a constant rate of drug permeation 
one needs to maintain the drug concentration on the surface of the 
stratum corneum (Cd)  consistent  and  substantially  greater  than  the 
drug concentration in the body (Cr) i.e.Cd>Cr
Under such conditions equation is reduced to
dQ
dt
=Ps Cd
The  rate  of  skin  permeation  dQ/dt becomes  a  constant  if  the 
magnitude of Cd remains fairly constant throughout the course skin 
permeation. To maintain Cd at a constant value it is necessary to make 
drug release at a rate (Rd) that is either constant or always greater than 
the rate of skin uptake (Ra) i.e.   Rd>Ra
By making Rd greater than Ra, the drug concentration of the 
skin surface, (Cd) is maintained at a level equal to or greater than the 
equilibrium  (or  saturation).  Solubility  of  the  drug  in  the  stratum 
corneum (Ces) i.e.  Cd> Ces and a maximum rate of skin permeation 
dq/dt is expressed as
 dQdt m=Ps C
es
The  maximum  skin  permeation  rate  depends  upon  the 
permeability coefficient and equilibrium solubility of drug in stratum 
corneum. Thus permeation appears to be stratum corneum limited.
FACTORS AFFECTING BIOAVAILABILITY OF TDDS
It consists of physiological and formulation factors
PHYSIOLOGICAL FACTORS
Stratum corneum
Transdermal bioavailability depends upon the barrier function 
of the stratum corneum. For very lipophilic compounds, it is generally 
believed that transport is limited not by diffusion across the stratum 
corneum, but rather by kinetics with which the molecule leaves the 
membrane and enters the underlying viable epidermis.
Anatomic site
The extent of absorption depends upon the anatomical sites to 
which the compound is applied. Likewise in TDDS, certain regions 
are significantly more permeable.
Skin condition and disease
Stages in barrier function due to skin diseases generally result 
either from alteration of the lipid/protein composition of the stratum 
corneum
Age
Like anatomic site,  skin age is  also believed to impact  upon 
percutaneous absorption and transdermal bioavailability.
Skin metabolism
Presystemic  metabolism  in  the  skin  can  obviously  modify 
transdermal drug bioavailability.
Skin irritation and sensitization
These responses are provoked by such diverse stimuli such as 
UV radiation, soaps, poisons, and of course, tropically applied drugs 
and other components of transdermal formulations.
FORMULATION FACTORS
Physicochemical property of transport
Permeation  through  the  stratum  corneum  occurs  by  passive 
diffusion, a process well defined by ficks first law and second law. 
The rule of the formulation and that of the physicochemical properties 
of  the  drug  on  transdermal  bioavailability  can  now  be  readily 
appreciated  because  at  steady  state,  there  is  direct  relationship 
between J and plasma concentration (Css) achievable.
Rate in A*J= Rate out Cl*Css
Where Cl is the drug clearance and it follows J, the instantaneous flux, 
which depends upon two parameters properties of the formulation and 
of the drug (i.e. Kp and Cr) directly determines that the drug target 
plasma concentration is  attainable  or  not  when the  area  of  contact 
between the delivery system and the skin (A) is reasonable.
BASIC COMPONENTS OF TDDS8
The  various  materials  used  in  TDDS  are  on  the  basis  of 
functional  classification  of  the  various  components.  The  basic 
components  of  transdermal  devices  are  polymeric  matrices  or 
reservoirs, drug, permeation enhancers and other excipients.
Polymers for Transdermal Delivery
9Polymers  are  the backbone of  the transdermal  drug delivery 
system.  The polymer controls the release of drug from the devices. 
The following criteria should be satisfied for a polymer to be used in 
transdermal system.
 Drug solubility and diffusivity in the polymer.
 The desired drug loading and its effect on polymer integrity.
 Compatibility of the polymer with necessary excipients, such as 
solvents and skin permeation enhances for the drug.
 Skin compatibility: the effect  of moisture occluded under the 
polymer formulation.
 Mechanical  properties:  softness,  flexibility,  conformability  to 
skin and mechanical integrity.
 Ease of fabrication.
 Toxicity and purity.
 Cost and availability.
It  is  rare  to  find  a  commercial  polymer  that  satisfies  all  the 
above criteria for polymer selection. Hence various techniques have 
been employed to modify the polymer properties and thus drug release 
rates.
Cross linked polymers:  The higher the degree of cross linking the 
more dense the polymer and slower the diffusion of drug molecule 
through the matrix. Cross-linking may be achieved chemically using 
cross –linking agent or by irradiation.
Polymer blends: The blended polymer combines the advantages of 
individual polymers. The potential advantages include easy fabrication 
of devices, manipulation of drug loading and other device properties 
such as hydration, degradation and mechanical strength.
Plasticizers: Plasticizers  are  used  to  reduce  the  stiffness  of  the 
polymer backbone thereby increasing the diffusion characteristics of 
the  drug.  In  selection  of  plastizers  care  must  be  taken  to  select  a 
material which is biocompatible.
COMMONLY USED POLYMERS IN TDDS10
Polyisobutylene
Polyisobutylene  is  a  highly  paraffinic,  non-polar  and 
amorphous  hydrocarbon  polymer  composed  of  essentially  straight 
chain macromolecules.  Physical properties of PIB change gradually 
with  increasing  molecular  weight,  the  liquids  are  become  more 
viscous, then change to balsam like sticky masses, and finally form 
elastomeric  solids.  PIB  is  soluble  in  hydrocarbon  solvents  and 
insoluble  in  polar  solvents.  PIB  exhibits  excellent  low-  transition 
temperature flexibility and oxidative stability.
Polyacrylates
Copolymers of acrylic and methacrylic acid ester can be most 
suitable for use as drug/ polymer matrix. Acrylate polymers, which are 
moderately polar, colorless and transparent, have excellent chemical 
resistance, thermal, light and oxidative stability.
Poly siloxanes
Polysiloxanes also referred to, as silicones are organo silicon 
polymers having si-o-si bonds along main chain and an alkyl group 
attached to a significant proportion of silicon atoms by silicon carbon 
bonds.  These  silicones  have  high  thermal  and  oxidative  stability, 
chemical inertness and very low surface tension.
Hydrogels
Hydrogels  are water swollen but  water  insoluble cross-linked 
networks of hydrophilic polymers.  They can absorb water  by more 
than 20% of its dry weight. The drug/hydrogel matrix can be prepared 
by either incorporating the drug in aqueous polymerization mixture or 
by equilibrium of the hydrogel in concentrated aqueous solution of the 
drug.
Polyvinyl Pyrrolidones
It is white, odourless and hygroscopic powder. It is available in 
different  viscosity  grades,  identified  by  K  values.  It  acts  as 
antinucleating agents  that  retard the crystallization of  a drug.  Thus 
they play a significant role in improving the solubility of a drug in the 
matrix  by  sustaining  the  drug  in  an  amorphous  form  so  that  it 
undergoes  rapid  solubilisation  by  penetration  of  the  dissolution 
medium.
Poly Vinyl Alcohol
It  is  cream  coloured  granular  powder  and  is  prepared  from 
polyvinyl  acetates.  PVA  is  available  in  different  grades  and  the 
viscosity is directly proportional to its molecular weight.
Ethyl vinyl acetate (EVA) polymers
EVA frequently used to prepare rate controlling membranes in 
transdermal  delivery  systems  because  it  allows  the  membrane 
permeability to be altered by adjusting the vinyl acetate content of the 
polymer.  They have been shown to be chemically  stable, non-toxic 
and biocompatible.
Cellulose derivatives
Many cellulose derivatives are employed for transdermal drug 
delivery  like  ethyl  cellulose,  methyl  cellulose,  cellulose  acetate 
phthalate, cellulose acetate butyrate, hydroxyl propyl methyl cellulose, 
sodium  carboxy  methyl  cellulose.  They  are  commonly  used  in 
combination with hydrophilic polymers like PVP, PEG etc.
SELECTION OF DRUG CANDIDATES FOR TDDS
The choice of drugs to be delivered is almost a difficult one and 
careful consideration should be given for selection of suitable drug 
molecules.  It  depends  on  the  physicochemical  and  biological 
properties of the drug.
Physicochemical properties of the drug
 The drug should have a molecular weight less than 750.
 It should have affinity for both lipophilic and hydrophilic phase.
 It should have low melting point.
Biological properties of the drug
 The drug should be potent with a daily dose of few mg/day.
 It should have short half life
 The drug should not stimulate an immune reaction in the skin.
 The  drug  must  not  induce  a  cutaneous  irritant  or  allergic 
response.
 The drug having high first pass metabolism is suitable candidate 
for TDDS.
PENETRATION ENHANCERS
The success of transdermal drug delivery depends on the ability 
of  the  drug  to  permeate  skin  in  sufficient  quantities  to  achieve 
required therapeutic plasma levels. Unfortunately many drugs do not 
possess intrinsically, any ability to cross the skin, and ways must be 
found  to  modify  the  barrier.  This  can  be  achieved  by  the  use  of 
permeation  enhancers  or  physically  by  iontophoresis  and 
sonophoresis.
Chemical penetration enhancers
The  penetration  enhancers  are  agents  that  increase  the 
permeability  of  the  skin  or  substances  that  temporarily  reduce  the 
impermeability of the skin.
The properties of an ideal penetration enhancer are
 Pharmacologically inert 
 Odourless, tasteless, colorless
 Non-toxic, non-irritating, nonsensiting and non allergic
 Rapid  onset  of  action,  predictable  and  suitable  duration  of 
action for drug used
 Rapidly incorporated into the delivery system.
 Following  removal  of  enhancer,  the  stratum corneum should 
immediately and fully recover its normal barrier property
 Chemically and physically compatible with the delivery system
 Inexpensive and cosmetically acceptable
Commonly Used Chemical Enhancers
1. Sulfoxides and similar compounds
Ex: dimethyl sulfoxide (DMSO), isopropyl myristate(IPM)
2. Pyrrolidones
Polyvinyl pyrrolidone
3. Azones
4. Surfactant 
Anionic laurate ions have the greatest penetration and strongest 
permeation promotion action.
OTHER EXCIPIENTS
Adhesives
The adhesives should be having following properties
1. Excellent contact with the skin.
2. Non-irritant, physically and chemically inert to the drug.
3. Should be easily removed.
4. Should not affect permeation process.
5. Should be non-irritant, non-sensitizing
Pressure sensitive adhesives  (PSA) have found application in 
transdermal  drug  delivery  because  of  the  need  to  intimate  contact 
between the transdermal system and skin surface. The adhesive bond 
formation involves  a  liquid  like  flow process  resulting in  adhesive 
wetting of the skin surface upon application of pressure.  When the 
pressure  is  removed,  the  adhesive  sets  in  that  state.  The PSA is  a 
characteristic of a visco elastic material, significantly above its glass- 
transition temperature.
Commonly  employed  PSA  in  TDDS  include  acrylate 
copolymers,  polyisobutylene  and  polysiloxanes.  Acrylic  –based 
adhesives are less irritating than silicone adhesives and the migration 
of  ingredients  into  the  adhesive  during  storage  may  also  be  less 
compared to other types.
Backing Layer
The backing layer must be impermeable to the drugs and other 
components of the device and also it should be impermeable to water 
vapour i.e. occlusive. The most commonly used backing materials are 
polyester  and  polyethylene  films.  The  films  can  be  either  clear 
(Estraderm) flesh coloured (Catapres-TTS) or metallized (Transderm 
scop) . Other non-porous plastics with similar properties could equally 
well be used. If the entire area, under the patch is active and the patch 
is not extensively large, then it is probably most convenient to use an 
occlusive backing. If the patch has a central area, containing the drug 
surrounded by a ring adhesive and the size of the patch is relatively 
large,  the  wearers  comfort  may  be  increased  by  having  a  backing 
material that is non occlusive.
Peel Strip
The peel strip prevents drug loss when it has irrigated into the 
adhesive  layer  on  storing  and  protects  the  finished  device  against 
contamination. The requirements for the peel strip are essentially the 
same as those for occlusive backing. The impermeable easily peelable 
films are made of polyester, foils etc.
TECHNOLOGIES OF TRANSDERMAL DRUG DELIVERY 
SYSTEMS6
Several  technologies  have  been  successfully  developed  to 
provide mechanism of rate control over the release and transdermal 
permeation  of  drugs.  To  be  precise,  there  are  two concepts  in  the 
design  of  TDDS  namely  skin  controlled  device  (matrix  type)  and 
system controlled device (reservoir type). The others are extensions of 
these two concepts.
Matrix System
It is designed to rely on the skin to control the rate at which 
drug  diffuses  into  the  body.  Skin  controlled  devices  are  typically 
monolith  systems  that  incorporate  a  drug  in  matrix  layer  between 
frontal and backing layer. The polymer matrix controls the release rate 
(proportional  to the square root  of time)  which is generally greater 
than permeation rate across the skin.
Membrane System
The transdermal system provides majority of the control of the 
rate of drug input to the body. System controlling devices contain a 
rate controlling membrane and drug (usually in liquid or general form) 
in a reservoir,  backing,  adhesive and protective layer.  This  type of 
system  is  beneficial  when  the  desired  rate  of  drug  transport  is 
considerably less than that through the skin.
Polymer Membrane Permeation - Controlled System
In  this  system,  the  drug  reservoir  is  encapsulated  in  a 
compartment molded from a drug impermeable backing layer and a 
rate controlling polymeric membrane.
In the drug reservoir compartment, the drug particles are either 
dispersed in a solid polymer matrix or suspended in an unleachable, 
viscous liquid medium. On the external surface, a thin layer of drug 
compatible adhesive polymer. e.g.: silicone or polyacrylate adhesive is 
applied  to  provide  an  intimate  contact  between  device  and  skin 
surface.
Matrix Diffusion Controlled Systems
The  drug  reservoir  in  this  type  of  device  is  formed  by 
homogenously  dispersing  the  drug  particles  in  a  hydrophilic  or 
lipophilic polymer and the medicated polymer is then molded into a 
medicated disc and then glued to a base plate, which is sealed to a 
drug  impermeable  backing.  Most  of  these  systems  do  not  have 
adhesive over layers but instead possess a peripheral adhesive ring.
Adhesive Diffusion Controlled Systems
In this the drug reservoir is formulated by directly dispersing 
the drug in an adhesive polymer on a flat sheet of drug impermeable 
backing to form a thin drug reservoir layer. Layers of non medicated 
rate controlling adhesive polymer of constant thickness are applied to 
produce an adhesive diffusion controlled drug delivery system.
Microreservoir or Microsealed Controlled System
These systems are a combination of the reservoir  and matrix 
dispersion  type  drug  delivery  systems.  In  these  systems,  drug 
dispersions is prepared by suspending the drug in an aqueous polymer 
solution and then the drug suspension is dispersed homogenously into 
lipophilic  polymer  by  high  shear  mechanical  force,  to  form 
microscopic spherical reservoir with the drug entrapped. Cross linking 
the polymer chains by the addition of polymeric cross linking agents 
stabilizes this unstable dispersions. This matrix is then attached to an 
adhesive  foam  (flexible)  backing.  The  system  has  a  peripheral 
adhesive ring
FIG 3
Different types of transdermal drug delivery systems
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VARIOUS APPROACHES TO INCREASE DRUG 
PENETRATION11
Drug absorption across the skin is very low due to the stratum 
corneum  (the  main  barrier  for  drug  absorption  across  the  skin). 
Overcoming the penetration barrier would significantly improve the 
development of an efficient transdermal drug delivery system. Several 
techniques have been developed, or are under development, to bypass 
the  stratum  corneum.  The  most  common  approach  has  been  the 
inclusion of chemical permeation enhancers (e.g.:isopropyl myristate) 
in topical formulation. These substances increase the drug penetration 
by  altering  skin  barrier  functions;  in  particularly,  this  absorption 
promotes  target  the  outermost  layer  of  epidermis,  the  stratum 
corneum. 
However, from a pharmaceutical stand point although chemical 
enhancers are appealing because they may be readily incorporated into 
a formulation,  they suffer  from a number  of  drawbacks because to 
achieve their goal (i.e. to perturb the skin barrier). Such substances are 
either irritating or induce an inflammatory reaction in response to the 
application  to  the  barrier.  Furthermore,  their  nonselectivity  means 
once the skin barrier is compromised, the entry of substance other than 
active drug is also facilitated.  Other methods used for getting drugs 
into the blood stream quickly and efficiently through the skin include 
iontophoresis, ultrasound, radiofrequencies and micro needles.
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Iontophoresis
It  applies a small  voltage (typically 10 V or less) continuous 
constant current (typically 0.5m A/ cm2) to push a charged drug into 
skin or  other  tissue.  Iontophoresis  can enhance delivery by driving 
charged compounds across the skin by a direct interaction with the 
electric field. Those with the greatest charge, and smaller molecules, 
get across quickest. The potential of this technique is recently being 
rediscovered  for  transdermal  systemic  delivery  of  ionic  drugs 
including peptides and oligonucleotides, which are normally difficult 
to administer, by parenteral route. The technique has been observed to 
enhance transdermal permeation of ionic drugs several fold, and this 
can expand the horizon of transdermal  controlled drug delivery for 
systemic  medication.  Besides  the typical  advantages of  transdermal 
delivery,  iontophoresis  presents  a  unique  opportunity  to  provide 
programmable drug delivery.
This  is  because  the  drug  is  delivered  in  proportion  to  the 
current, which can be readily adjusted. Such dependence on current 
may also make drug absorption via iontophoresis less dependent on 
biological  variables.  Also  patient  compliance  can  be  improved  by 
including  electronic  means  to  remind  patients  to  replace  the  dose 
when required.
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Electroporation
It  involves application of high voltage pulse for a very short 
duration  to  permeabilise  the  skin.  The  change  in  the  membrane 
involves structural arrangement and conductance leading to temporary 
loss of pores. Approximately 100 multilamellar bilayers of the stratum 
corneum need about 100v pulses for electroporation or 1v per bilayer.
Sonophoresis
Ultrasound  has  been  used  to  treat  a  wide  range  of  clinical 
conditions and to transport drugs to deeper tissues in the treatment of 
inflammatory  conditions.   The  technique  involves  placing  and 
massaging the area with an ultrasonic source. Recently sonophoresis 
has attracted lot of interest in transdermal delivery with the focus on 
peptide protein delivery.
Microfabricated Microneedles and Microchips Technology
Recently,  a  novel  method  was  developed  for  enhancing 
transport  of  molecules  across  the skin.  The micro fabricated  micro 
needles technology employs micron- sized needles made of silicon.
These micro needle arrays after  insertion into the skin create 
conducts for transport of drug across the stratum corneum. The drug 
after crossing the stratum corneum diffuses through the deeper layers 
and taken  up  by  the  capillaries  for  systemic  administration.  Micro 
needles penetrate the skin about 10-12 µm deep inside the skin but do 
not reach the nerves found in deeper tissue, so are painless. The micro 
needles were made using the micro fabrication technology similar as 
making of integrating circuits. A microprocessor is attached to a tiny 
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pump for delivering tiny amounts of the drug. The microprocessor and 
pump automatically injects the right dosage of drug. Micro needles 
have extremely sharp tips with a radius of curvature less then 1 mm 
facilitating  easy  piercing  into  the  skin.  The  micro  fabrication 
technique can be easily modified to make longer or shorter needles 
according to the requirements.
Laser Radiation
This method involves direct and controlled exposure of a laser 
to the skin which results in the ablation of stratum corneum without 
significantly damaging the underlying epidermis. Removal of stratum 
corneum by this method has been shown to enhance the delivery of 
hydrophilic and lipophilic drugs.
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DRUG PROFILE
METOPROLOL TARTRATE12
OCH2
CH2CH2OCH3
CH2NHCH(CH3)2
OH
H COOH
H OH
COOH
HO H
Category : Cardioselective, antihypertensive
Molecular Formula : (C15H25NO3)2.C4H6O6
Molecular Weight : 684.82
IUPAC Name : 1-isopropylamino -3-p - (2- methoxyethyl) 
   phenoxy - propan -2-ol (2R, 3R) tartrate.
Dose : 100-450 mg daily, in divided doses.
M.P : 121°-124°
PHARMACOKINETICS13
Absorption :  Orally administered metoprolol tartarte is absorbed  
  rapidly and almost completely absorbed from the G.I. 
  tract; food enhances the absorption.
Distribution : Distributed widely throughout the body; about 12% is 
   plasma- bound.
Metabolism : Metabolized in the liver.
Excretion : About 95% of a given dose of metoprolol is excreted 
  in urine within 72 hours, largely as metabolites.
PHARMACODYNAMICS
35
Metoprolol is  classified as cardioselective beta1 agonist;  drug 
may  reduce  blood  pressure  by  blocking  adrenergic  receptor,  thus 
decreasing cardiac  output,  by  decreasing  sympathetic  outflow from 
CNS or by suppressing renin release.
Description :  White  crystalline  powder  or  colourless  
  crystals.
Solubility : Very soluble in water, freely soluble in 
  ethanol (95%), chloroform and in 
  dichloromethane, slightly soluble in acetone, 
  practically insoluble in ether.
Bioavailabilty14,15 : 38± 14%
Urinary Excretion : 10±3%
Volume of Distribution : 4.2±0.7
Half Life : 3.2±0.2 hrs.
Storage :  Store  in  tight,  light  resistant  container  at 
15-30°c  and  metoprolol  tartrate  injection 
should be stored at a temperature of 30°c or 
less, preferably 15-30°c, freezing of injection 
should be avoided.
Standards :  Metoprolol  tartrate  contains not  less  than 
99%  and  not  more  than  101%  of 
(C15H25NO3)2C4H6O6.  Calculated  with 
reference to the dried substance.
pH : Between 2&7, determined in a 2% w/v solution.
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POLYMER PROFILE
16POLY VINYL PYRROLIDONE
Non proprietary names:
BP : Povidone
JP : Povidone
Ph Eur : Povidonum
USPz : Povidone
Synonyms : E1201; Kollidon: plasdone; PVP: Poly 
    [1- (2-oxo-1-pyrrolidinyl) ethylene];
  polyvidone; 1-vinyl-2- pyrrolidionone 
  polymer
3. Chemical name :1-Ethenyl-2-pyrrolidinone homo polymer 
and CAS Registry    [9003-39-8]
number
4. Empirical formula : (C6H9No)n
5. Molecular weight : 2500-3,000,000
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Table 1: Approximate molecular weights for different grades of 
Povidone
K value Approximate molecular wt
12 2500
15 8000
17 10,000
25 30,000
30 50,000
60 400,000
90 1,000000
120 3000000
6. Functional category
Disintegrant, dissolution aid, suspending agent, tablet binder
7. Description
Povidone  occurs  as  a  fine,  white  to  creamy-white  colored, 
odorless or almost odorless, hygroscopic powder. Povidones with K-
values equal to or lower than 30 are manufactured by spray-drying 
and occur as spheres.
8. Typical properties
Acidity/alkalinity : pH = 3.0-7.0 (5% w/v aqueous solution)
True density : 1.180g / cm3
Melting point : Softens at 150oC
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Moisture content
Povidone is very hygroscopic significant amounts of moisture 
being absorbed at low relative humidities.
9. Solubility
Freely soluble in acids, chloroform, ethanol, ketones, methanol 
and water, practically insoluble in ether, hydrocarbons and mineral oil.
10. Stability and storage conditions
Povidone darkens to some extent on heating at 150oC, with a 
reduction in aqueous solubility.  It is stable to a short cycle of heat 
exposure around 110-130oC. Steam sterilization of aqueous solution 
does not alter its properties
11. Safety
Povidone  has  been  used  in  pharmaceutical  formulations  for 
many  years,  being  first  used  in  the  1940s  as  a  plasma  expander, 
although it has now been superseded for this purpose by dextran.
12. Application in pharmaceutical formulation or technology
 It is primarily used in solid-dosage forms
 In  tableting,  povidone  solution  are  used  as  binders  in  wet 
granulation processes
 It is also added to powder blends in the dry from and granulated 
inside  by  the  addition  of  water,  alcohol  or  hydro  alcoholic 
solutions.
 It is used as a solubilizer in oral and parenteral formulations and 
has  been shown to  enhance  dissolution  of  poorly  soluble  drugs 
from solid dosage forms
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 Used as a suspending, stabilizing or viscosity-increasing agent in a 
number of topical and oral suspensions and solutions.
 The solubility of a number of poorly soluble active drugs may be 
increased by mixing with povidone.
Special grades of pyrogen-free povidone are available and have 
been used in parenteral formulations
CELLULOSE ACETATE BUTYRATE17,18
Ph Eur : Cellulosi Acetas Butyras
Synonym : Cabufocon 
Molecular weight : 16000
Functional category : coating agent, extended release agent.
Description :  a white, yellowish white or greyish white 
powder or granules, slightly hygroscopic.
TYPICAL PROPERTIES
Melting point :  127-1470c
Specific gravity :  1.16
Solubility : insoluble in water and alcohol, soluble in 
acetone, formic acid , chloroform and in a 
mixture of equal volume of methanol and 
methylene chloride
Stability and storage : cellulose acetate butyrate is stable if stored 
in a well closed container in a cool, dry 
place. It hydrolysis slowly under prolonged 
adverse conditions such as high temperature 
and humidity.
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Compatability : compatabile with plasticizers dibutyl 
phthalate, diethyl phthalate, butyl benzyl 
phthalate, tricresyl phosphate.
Applications
 Widely  used  in  pharmaceutical  formulations  in  sustained 
release application.
 Used in transdermal drug delivery systems
 Used in enteric film material
HYPROMELLOSE
Non proprietary names
BP        : Hypermellose
JP         :   Hydroxypropyl methyl cellulose
Ph Eur    :   Hypromellosum
USP       :   Hypromellose
Synonyms:
Benecel  MHPC,  hydroxypropyl  methyl  ether,E464, 
hydroxypropyl methyl cellulose,  HPMC, Methocel,  methylcellulose, 
propylene  glycol  ether,  methyl  hydroxypropylcellulose,  metalose, 
pharmacoat, spectracel 6, spectracel 15, Tylopur.
Chemical name:
Cellulose, 2-hydroxypropyl methyl ether.
Molecular weight : 10 000 – 1500 000
Functional category:
Coating  agent,  film  former,  rate  controlling  polymer  for 
sustained release,  stabilizing agent,  suspending agent,  tablet  binder, 
viscosity- increasing agent.
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Description
Hypermellose  is  an odourless  and tasteless,  white  or  creamy 
white fibrous or granular powder.
Typical properties
Acidity / alkalinity : pH  5.5 – 8.0 for a 1% w/w aqueous 
  solution.
Ash : 1.5- 3.0% depending upon the grade.
Density : 1.326 g/cm3
Melting point : browns at 190- 2000c; 
 chars at 225-2300C
Glass transition temperature : 170- 1800 c.
Moisture content : Hypermellose absorbs moisture from 
the atmosphere, the amount of water 
absorbed depending and relative 
humidity of the surrounding air.
Solubility : Soluble in cold water, forming a 
viscous colloidal solution, practically 
insoluble in chloroform, ethanol(95%) 
and ether, but soluble in mixtures of 
ethanol and dichloromethane, 
mixtures of methanol and 
dichloromethane, and mixtures of 
water and alcohol.
Specific gravity         : 1.26
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Stability and storage conditions
Hypromellose  powder  is  a  stable  material,  although  it  is 
hygroscopic after drying. Solutions are stable at PH 3-11. Increasing 
temperature reduces the viscosity of the solutions. Aqueous solutions 
are  comparatively  enzyme-  resistant,  providing  good  viscosity 
stability  during long term storage.  Hypermellose  powder should be 
stored in a well- closed container, in a cool, dry place.
Incompatibilities
Hypermellose  is  incompatible  with  some  oxidizing  agents. 
Since it is nonionic, hypermellose will not complex with metallic salts 
or ionic organics to form insoluble precipitates.
Safety
Hypermellose is  widely used as excipient  in oral  and topical 
pharmaceutical formulations. It is also used extensively in cosmetics 
and  food  products.  Hypromellose  is  regarded  as  nontoxic  and 
nonirritant material, although excessive oral consumption may have a 
laxative effect.
Applications
 It is widely used in oral and topical formulations, particularly 
ophthalmic formulations.
 It  is  used as  an emulsifier,  suspending agent,  and stabilizing 
agent in topical gels and ointments.
 As a protective colloid ,  it  can prevent droplets and particles 
from  coalescing  or  agglomerating,  thus  inhibiting  the 
formulation of sediments.
43
 Hypermellose is also used in the manufacture of capsules, as an 
adhesive  in  plastic  bandages,  and  as  wetting  agent  for  hard 
contact  lenses.  It  is  also  widely  used  in  cosmetics  and  food 
materials.
ETHYL CELLULOSE
Synonyms : aquacoat ECD, aqualon E 462, ethocel, 
surelease.
Chemical name : cellulose ethyl ether
Description : Ethylcellulose is a tasteless, free flowing, 
white to light tan-coloured powder.
Density : 0.4 g/cm3
Glass transition : 129 – 133°c
temperature
Solubility : Ethyl cellulose is practically insoluble in 
glycerin, propylene glycol, water.
Ethyl cellulose that contains less than 46.5% 
of  ethoxy  groups  is  freely  soluble  in 
chloroform. Methyl acetate, tetrahydrofuran, 
aromatic hydrocarbons and ethanol.
Freely  soluble  in  ethanol,  ethyl  acetate, 
methanol, toluene.
Specific gravity : 1.12 – 1.15 g/cm3
Viscosity : 5 – 100m pascals ( 7 – 100cp)
Functional category: Coating agent, flavouring fixative, tablet 
binder,  tablet  filler,  viscosity-increasing 
agent.
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Stability and storage conditions:
Ethyl  cellulose  is  stable,  slightly  hygroscopic  material. 
Chemically  resistant  to  alkali,  more  sensitive  to  acidic  materials. 
Ethylcellulose is subjected to oxidative degradation in the presence of 
sunlight or UV light at elevated temperature. This may be prevented 
by use of antioxidant and chemical additives that absorb light in the 
230-340nm range.
It should be stored at a temperature not exceeding 32ºC in a day 
area away from all sources of heat.  It  should not be stored next to 
peroxides or other oxidizing agents.
Safety:
Ethyl cellulose widely used in oral and topical pharmaceutical 
formulations. It is also used in food products. Ethyl cellulose is not 
metabolized  following  oral  consumption  and  is  therefore  a  non-
calorific substance. Because ethyl cellulose is not metabolized it is not 
recommended for parenteral products; parenteral use may be harmful 
to the kidneys.
Ethyl cellulose generally regarded as a nontoxic non-allergenic 
and non irritating material. An ethyl cellulose is not considered to be a 
health hazard, the WHO has not specified an acceptable daily intake.
Incompatibilities
With paraffin wax and microcrystalline wax.
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Applications in pharmaceutical formulations:
 Hydrophobic coating agent for tablets and granules
 Modified the release of drug
 To mask the unpleasant taste of drug
 To improve the stability of formulation
 Thickness agent in creams, lotions, gels
 Used in cosmetics, food products.
 Binder in tablets.
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LITERATURE  REVIEW
Ubaidulla .U et al19 (2007) prepared transdermal therapeutic system 
of carvedilol and the effect of hydrophilic and hydrophobic matrix on 
invitro  and in  vivo characteristics  were  studied.  The patches  made 
with polymers  ethyl  cellulose  –poly vinyl  pyrrolidone and eudragit 
RL- eudragit RS have great utility and use viable option for effective 
and controlled management of hypertension.
Gannu .R et al20 (2007) developed nitrendipine transdermal patches 
and subjected to  in vitro and  in vivo characterization. Formulations 
composed  of  Eudragit  RL100-  HPMC  combination  and  Eudragit 
RS100 and HPMC combination were prepared with 6% carvone as 
penetration enhancer and 15% propylene glycol as plasticizer. From 
the  results  it  can  be  concluded  that  nitrendipine  matrix  type 
transdermal  patches  could  be  prepared  with  required  flux  having 
suitable mechanical properties.
Zhao  .J.H  et  al21 (2007) prepared  a  novel  transdermal  patch 
incorporating isosorbide di nitrate with bisoprolol. The in vitro and in 
vivo release profile showed that the combination therapy of nitrate and 
bisoprolol  has  shown  benefits  for  treatment  of  hypertension  than 
either drug alone.
Tanwar  .Y.S.  et  al22 (2007) studied  on  the  development  and 
evaluation  of  carvedilol  transdermal  patches.  The  patches  of 
carvedilol with HPMC drug reservoir were prepared and membranes 
of ERL 100 and ERS 100 were cast to achieve controlled release. The 
effects  of  non-ionic  surfactants  tween  80  and  span  80  on  drug 
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permeation were studied. Span 80 exhibit more release enhancement 
compared to tween 80.
Mundargi .R.C. et al23 (2007) studied the possibility of using xanthan 
films as a matrix system for transdermal delivery of atenolol. The in 
vitro release profile showed a fickian diffusion trend.
Saraf  Swarnalatha  et   al24 (2006) has  compared  the  effect  of 
permeation of timolol maleate using polymer hydroxypropyl methyl 
cellulose and ethyl cellulose combination and with polyvinyl alcohol. 
The  studies  concluded  that  reservoir  followed  zero  order  kinetics 
while  matrix  followed  first  order  kinetics.  In  matrix  type  patch 
polyvinyl alcohol is more permeable.
Gupta  .S.P  and  Jain  .S.K25 (2006) studied  about  the  polymeric 
matrix  system for  TDDS of atenolol  using different  ratios of  ethyl 
cellulose-  HPMC and films  were subjected  to  in  vivo and  in  vitro 
studies.  The  drug  release  from the  films  was  found  to  be  fickian 
diffusion type and exhibiting linear relationship between drug release 
and  square  root  of  time.  It  could  be  conclude  that  the  designed 
polymeric matrix of TDDS of atenolol could be used for effective and 
prolonged duration. 
Rathore RPS et al26 (2006)  has developed transdermal matrix type 
patches  of  terbutaline  sulphate  using  ethyl  cellulose  and  PVP 
combination  and  cellulose  acetate  –  PVP  combination.  The  drug 
release  from both  the  systems  follows  Higuchi  kinetics  and higher 
release  rates  and permeability  was achieved with cellulose  acetate- 
PVP patches than EC-PVP.
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Gupta  .S.P  and  Jain  .S.K27 (2005) studied  the  effective  and 
controlled  transdermal  drug  delivery  of  metoprolol  tartarate  with 
polymers Eudragit RL and HPMC. The system comprising ERS and 
HPMC in 40:60 ratio exhibited drug skin permeation 87.5mcg/h/cm. 
This  transdermal  system was evaluated  for  its  in  vivo performance 
studies and compared its drug plasma profile with those obtained with 
oral multiple doses of conventional tablets of metoprolol tartarate. The 
TDDS exhibited better  and constant  plasma profile as compared to 
oral administration.
Aquil  .M  et  al28 (2005) prepared  transdermal  drug  delivery  of 
labetolol hydrochloride and evaluated for in vitro, ex vivo and in vivo 
characteristics using ERS 100 –ERL 100 combination and ERL100 – 
PVP K 30 combination. The maximum drug release was observed in 
24 hours.
Gupta  .S.P  and  Jain  .S.K29 (September  2004) developed  matrix 
membrane type transdermal drug delivery of atenolol using different 
combinations of polymers Eudragit RL with PVP and PEG400. These 
preparations were evaluated for  in vitro studies and revealed that the 
designed  polymeric  matrix  could  be  successful  with  improved 
performance.
Mutalik .S and Udupa .N30 (March 2004) developed matrix  type 
transdermal patches containing glibenclamide using different ratios of 
EC/PVP and ERL100 and ERS 100 by solvent evaporation technique. 
The  pharmacokinetic  evaluation  showed  that  the  patches  could 
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maintain  almost  steady  state  concentration  of  drug  within  the 
pharmacologically effective range for prolonged period of time.
Narasimhamurthy  .S  and  Shobha  Rani  .R  Hiremath31 (2001) 
studied  the  formulation  and  evaluation  of  controlled  release 
transdermal  patches  of  theophylline-  salbutamol  sulphate  using 
HPMC as polymer. It was evident from the results that the formulation 
of TDDS for simultaneous delivery of theophylline and salbutamol is 
feasible  and system is  capable  of  maintaining therapeutic  levels  of 
drug in the blood.
Narasimhamurthy .S and Shobha Rani R. Hiremath32 (March 21, 
2001)  studied  the  effect  of  physical  and  chemical  permeation 
enhancers in transdermal delivery of terbutaline sulphate. Among the 
chemical  permeation  enhancers  isopropyl  myristate,  tween80  and 
sodium  lauryl  sulphate,  isopropyl  myristate  produced   higher 
permeation.  Magnetophoresis  is  used  as  physical  enhancer.  The 
presence  of  magnets  on  permeation  of  the  drug  was  found  to  be 
similar to that of isopropyl myristate.  
Kulkarni  et  al33 (2000)  studied  the  comparative  evaluation  of 
polymeric  films  for  transdermal  application.  It  includes  the 
preparation and characterization of polymeric films of PVP, EC, ERS 
100 and EVA. All the polymers used for the fabrication have good 
film  forming  properties  ,  films  were  thin,  flexible,  smooth  and 
transparent and films are permeable to drug and drug diffusion was 
extended over a longer period of time at a controlled state. Among the 
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4 films prepared EC films was found to be good with respect to drug 
diffusion. 
Kanikkannan  et  al34 (2000) studied  on  transdermal  iontophoretic 
delivery of timolol maleate in albino rabbits. The use of transdermal 
iontophoresis  is  a promising technique for the systemic delivery of 
water soluble and ionic drugs of relatively large molecular size. The 
present  study  investiges  the  skin  pretreatment  with  azone  and 
iontophoresis on the pharmacodynamic effect  of timolol  maleate  in 
vivo in rabbits. Iontophoresis in combination with azone can increase 
the  transdermal;  release  of  timolol  maleate  there  by  the  required 
transport rate can be achieved by lower drug content. 
Sridevi .S et al35 (2000)  developed acrylate based transdermal drug 
delivery  for  glibenclamide  and  evaluated  its  pharmacodynamic 
performance in  male  wister  rats.  The drug embedded  in polymeric 
matrix of polymethacrylate and ethyl cellulose was evaluated for its 
hypoglycemic  activity.  TDDS  significantly  sustained  the 
hypoglycemic  activity  for  24hours  when  compared  to  oral 
administration where the effect declined after 8 hours.
Oh .S.Y et al36 (1999) studied the enhanced transdermal drug delivery 
of  zidovudine  using  iontophoresis  and  penetration  enhancers  were 
compared. These enhancers worked synergistically with iontophoresis 
in the transdermal transport.
Jia-You  Fang  et  al37 (1999) studied  transdermal  iontophoretic 
delivery  of  diclofenac  sodium  from  various  polymers  like  PVP, 
HPMC,  PVP-HPMC.  The  excised  skin,  human  skin  as  well  as 
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cellulose  membranes  were  used  to  examine  the  in  vitro drug 
permeation  and  microdialysis  was  used  to  monitor  the  drug 
concentration  in  vivo. They  showed  binary  system  having  higher 
percentage than that of single polymer vehicle.
Rao  .P.R  and  Diwan  .P.V38 (1998) studied  the  formulation  and 
evaluation  of  polymeric  films  of  diltiazem  hydrochloride  and 
indomethacin fabricated using ethyl cellulose – polyvinyl pyrrolidone 
films. The invitro skin permeation profiles showed increase of initial 
concentration of drugs in the films and also with the concentration of 
polyvinyl pyrrolidone.
Rama  Rao  et  al  .P39 (1997)  studied  the  influence  of   various 
permeation  promoters  on  the  in  vitro percutaneous  absorption  of 
indomethacin.  The  enhancers  used  includes  ethanol,  PEG600,  PG, 
oleic  acid  and IPM.  The  maximum solubility  was  observed in  the 
system  containing  ethanol/oleic  acid  (50:50)  and  ethanol  (40:60). 
Therefore permeation rate also increased in both cases.  From these 
results it may be concluded that the incorporation of oleic acid to a co-
solvent  system  of  ethanol  is  very  useful  to  improve  the  skin 
permeation rate of indomethacin.
Narasimhamurthy  .S  and  Mini  Satheesh40 (1997)  studied  the 
enhancer  synergism  of  propylene  glycol  in  terbutaline  sulphate  in 
transdermal drug delivery systems. It was observed that transdermal 
permeability  of  terbutaline  sulphate  across  the  human  skin  was 
enhanced with the increasing plasticizer concentration.
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Paranjothy .K.L.K and Thampi .P.P41 (1997) developed transdermal 
patches of verapamil hydrochloride using sodium carboxy methyl guar 
as polymer matrix using propylene glycol as plasticizer and  in vitro 
evaluation were done.
Bhatt .D.C et  al42 (1995)  had formulated transdermal  patches with 
matrix  drug  reservoir  films  using  ethyl  cellulose  :  polyvinyl 
pyrrolidone, Eudragit RL100: polyvinyl pyrrolidone, cellulose acetate 
butyrate : polyvinyl pyrrolidone. In vitro studies were done on ratskin 
and in vivo evaluation was done on dogs.
53
PURPOSE OF THE WORK
Systemic  hypertension represents  a  significant risk  factor  for 
the  development  of  atherosclerotic  coronary  artery  disease  and 
myocardial infraction, cerebro-vascular accidents and congestive heart 
failure. A major barrier for to the management of hypertension is the 
extent to which patients comply with treatment regimen
Metoprolol tartrate is a beta adrenoreceptor blocking agent used 
in the treatment of cardiovascular disorders. The drug has a short half-
life  of  3-4  hours  and  is  reported  to  show  extensive  first  pass 
metabolism  following  oral  administration  resulting  in  poor 
bioavailability. Long term therapy of hypertension using metoprolol 
tartarate orally may result in poor patient compliance because of low 
bioavailability and short plasma half-life.  This problem of the drug 
metoprolol  tartrate  can  be  minimized  by  the  formulation  of  the 
transdermal delivery system. Transdermally delivered drug provides 
the patients a unique and convenient dosing schedule while providing 
nearly constant serum levels of medication over a prolonged period. 
The  minimum  concentration  needed  to  produce  the  effective 
therapeutic concentration for metoprolol tartrate is in the range of 20-
100ng/ml.43
The ideal requirement of metoprolol tartrate with respect to its 
solubility, molecular weight, melting point, bioavailability and half-
life  etc  for  its  incorporation  into  matrix  type.  Polymeric  films  of 
transdermal delivery system prompted the selection of metoprolol for 
this study.
54
PLAN OF THE WORK
The  present  work  is  undertaken  to  prepare  and  evaluate  a 
transdermal delivery system for the drug metoprolol tartrate. It was 
planned to carry out this work as outlined below. 
 Solubility and compatibility studies for selection of polymers 
used for film casting. 
 Casting of plain films. 
 Preparation of drug incorporated polymeric films (matrix type 
using polymers CAB, PVP, HPMC and EC in different ratios)
 Evaluation of patches for physicochemical characteristics.
Physical characteristics
• Moisture content
• Moisture uptake
• Weight variation
• Drug content
• Film thickness
• Tensile strength
• Skin irritation test
In vitro release studies
Drug stability
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MATERIALS AND EQUIPMENTS
Table 2 Materials used
Materials Company
Metoprolol tartrate Gift from Astrazeneca
Cellulose acetate butyrate Glaxo (Kemphasol)
Poly vinyl pyrrolidone Loba Chemicals
Hydroxyl propyl methyl cellulose High media
Ethyl cellulose Kemphasol
Di n-butyl phthalate Ranbaxy
Isopropyl myristate Sd Fine Chemicals
Potassium dihydrogen phosphate Fischer Inorganic & Aromatic Ltd
Methanol Sd Fine Chem.
Chloroform Quligens Fine Chemicals
Ethanol Commercial Alcohol Inc
Aluminium foil Sd Fine Chemicals Ltd
Syringe 5 ml Core Pharmaceuticals
Ammonia Sd Fine Chem.
Calcium chloride Sd Fine Chem.
Potassium chloride Sd Fine Chem.
Cellulose membrane (0.2µ) Sartorius 
Mercury Ranbaxy
56
Table 3: Equipments used
Franz diffusion cell Fabricated
UV- visible spectrophotometer Jasco V-530
FT-IR spectrophotometer Jasco-410
Digital balance Denver Instrument
Hot air oven Lab Equipment Pvt Ltd
Magnetic stirrer Remi Motors
Circulating water bath From Dissolution Apparatus
Circular mould disc Fabricated
Vacuum desicator Tarrsons
Micropipette Electro Lab
Dissolution apparatus High Tech Labs
EXPERIMENTAL WORK
Standard graph of metoprolol tartrate44
Preparation of stock solution
10 mg of  metoprolol  tartrate  was  dissolved in  methanol  and 
made upto 100 ml to obtain 100mcg/ml working standard.
Calibration graph of metoprolol tartrate
Aliquots of 0.5 ml to 3.0 ml portions representing 5 to 30 mcg 
of drug were transferred to different 10 ml volumetric flask. To each 
flask methanol is added and made up to 10 ml. Then absorbance was 
measured  at  225  nm  against  a  blank  solution  prepared  in  similar 
manner without the addition of drug.
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Table 4 : Data of absorbances of standard graph
Sl. No. Concentration in mcg/ml Absorbance at 225 nm
1 5 0.104
2 10 0.201
3 15 0.296
4 20 0.405
5 25 0.492
6 30 0.581
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Fig  4
Calibration curve of metoprolol tartrate
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DEVELOPMENT OF PATCHES
In  the  present  study  matrix  type  transdermal  patches  of 
metoprolol  tartrate were  prepared by mercury substrate method. A 
flat  circular  glass  mould  was  fabricated  for  this  purpose.  The 
transdermal patches were prepared using polymers in different ratios.
Three types of polymeric patches were prepared using polymer 
combinations. It includes
Cellulose acetate butyrate – polyvinyl pyrrolidone
Ethyl cellulose- hydroxyl propyl methyl cellulose
Ethyl cellulose- Polyvinyl pyrrolidone
CAB and PVP patches  were  prepared by dissolving CAB in 
measured volume of chloroform and kept aside for 4 hours to facilitate 
the polymer to dissolve in the solvent. Then add specified quantities of 
PVP, DBP and isopropyl myristate as listed in table.5
The polymeric  solution of  EC and HPMC were prepared by 
dissolving  separately  in  methanol-  chloroform  (1:1)  mixture.  Both 
solutions  are  mixed  in  different  ratios  using  dibutyl  phthalate  as 
plasticizer. The polymeric solution of EC and PVP were prepared by 
dissolving in chloroform in different ratios.
A weighed amount of drug is dissolved in suitable solvent and 
dispersed in polymer mixture and this solvent is poured in to the ring 
placed on mercury surface in a Petri dish and solvent evaporation was 
controlled by covering with a funnel. After 24 hours the patches were 
removed and kept in dessicator to remove any adhering solvents, the 
films were cut in circular  disc with 3.8cm diameter.  These patches 
were wrapped in aluminium foil, packed in self sealing cover and kept 
in dessicator.
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Table: 5 : composition of transdermal patches
Formulation
MT 
in 
mg
CAB 
in 
parts
PVP 
in 
parts
EC 
in 
parts
HPMC 
in 
parts
DBP 
in % 
W/W
IPM 
in % 
W/W
F1 15 4.5 0.5 30 20
F2 15 4.0 1.0 30 20
F3 15 3.5 1.5 30 20
F4 15 3.0 2.0 30 20
F5 15 2.5 2.5 30 20
F6 15 2.0 3.0 30 20
F7 15 1.5 3.5 30 20
F8 15 4.5 0.5 30 20
F9 15 4.0 1.0 30 20
F10 15 3.5 1.5 30 20
F11 15 3.0 2.0 30 20
F12 15 2.5 2.5 30 20
F13 15 2.0 3.0 30 20
F14 15 1.5 3.5 30 20
F15 15 0.5 4.5 30 20
F16 15 1.0 4.0 30 20
F17 15 1.5 3.5 30 20
F18 15 2.0 3.0 30 20
F19 15 2.5 2.5 30 20
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EVALUATION OF TRANSDERMAL PATCHES
The prepared patches were evaluated for their physico-chemical 
parameters,  in  vitro diffusion  studies,  skin  irritation  and  stability 
studies.
Physicochemical parameters
1. Weight variation
As weight variation between the formulated patches can lead to 
difference in drug content and in vitro behaviour, a study was carried 
out weighing 5 patches in an electronic balance. The average weight 
of  a  patch  and  its  standard  deviation  was  calculated  by  using  the 
following formulae.
Average weight of each patches = total weight of 5 patches/5
Standard deviation  = ∑  x−X 2n−1
Where x = weight of individual patch
X = average weight
n = number of patches
2. Percentage of moisture content
The films were weighed individually and kept in a dessicator 
containing anhydrous  calcium chloride  at  room temperature  for  24 
hours. Individual films were weighed repeatedly until they showed a 
constant weight. The percentage of moisture content was calculated as 
the difference between initial and final weight with respect to the final 
weight.
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3. Percentage moisture uptake
Moisture uptake can influence the mechanical strength and drug 
release  of  the  transdermal  therapeutic  system.  It  was  done  by 
weighing the film and keeping in a dessicator at room temperature for 
24  hours  and  patches  were  removed  and  exposed  to  84% relative 
humidity( a saturated solution of potassium chloride) in a dessicator 
until a constant weight for the film was obtained. The percentage of 
moisture uptake was calculated as difference between final weight and 
initial weight with respect to final weight.
Percentage moisture uptake =final weight- initial weightfinal weight ×100
4. Drug content
A film was cut into small pieces, put into a 100ml buffer (PH- 
7.4)  and shaken continuously  for  24  hours.  Then the  solution  was 
filtered. After filtration, the drug content was estimated at wave length 
225nm.
5. Film thickness 
The thickness was measured at 5 different  places for 5 films 
using a dial caliper and mean value were calculated. 
6.Tensile Strength 
It was determined by using a modified pulley system. Weight 
was gradually increased so as to increase the pulley force till the patch 
broke. The percentage elongation before the patch broke was noted 
with the help of a magnifying glass on a graph paper and the tensile 
strength was calculated as kg/mm2.
In vitro permeation studies
63
In  vitro permeation  studies  were  performed  using  Franz 
diffusion  cell.  It  consists  of  a  donor  compartment  and  a  receptor 
compartment.  The  cellulose  membrane45 was  mounted  between  the 
donor compartment and receptor compartment  of the diffusion cell. 
The formulated patches were placed over the membrane. The receptor 
compartment of the diffusion cell was filled with phosphate buffer pH 
7.4.  The whole  assembly  was fixed on a  magnetic  stirrer,  and the 
solution in the receptor compartment was constantly and continuously 
stirred  using  magnetic  bead  at  50  rpm;  the  temperature  was 
maintained at 37 ± 10C. The samples were withdrawn at different time 
intervals  and  analysed  for  drug  content.  The  receptor  phase  was 
replenished with an equal volume of phosphate buffer at each sample 
withdrawal. The cumulative amount of drug permeated/cm2 of patches 
were plotted against time.
Fig 5
Franz Diffusion Apparatus
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Skin irritation studies
Patches were applied to the depilated skin of the back of two 
rabbits and secured using an adhesive tape. On one side blank patches 
were applied and on other side experimental  patches were secured. 
The animals were observed for any signs of erythemia or edema for a 
period of 48 hours.
Accelerated Stability Studies
To  any  rational  design  and  evaluation  of  dosage  forms,  the 
stability  of the active component  in the formulation must  be major 
criteria  in  determining  their  acceptance  or  rejection.  The  drugs 
instability by a physical appearance, colour, odour, taste or texture of 
the  formulation.  Scientific  data  pertaining  to  the  stability  of  a 
formulation leads to the prediction of the expected shelf life of the 
product  and  if  necessary  reformulation  of  the  dosage  form can  be 
done. 
Hence to determine the shelf life, formulations F7, F14, F19 were 
selected and stored at temperatures 250C and 370C for 30 days. The 
patches were evaluated for physico-chemical properties and their drug 
content and in vitro release in 10 days interval. 
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RESULTS AND DISCUSSION
Compatibility studies
IR
The presence of all characteristic peaks of metoprolol tartrate, 
in IR spectra obtained with metoprolol tartrate and the other excipients 
confirms the intactness of the drug in the polymer matrix.(fig.11,12 
and 13).
Thin layer chromatography: (TLC)
A thin layer chromatographic method was also carried to study 
the interaction between the drug and the polymer.  A single distinct 
spot at the same height for both drug and formulation was having the 
same  Rf value  of  0.428 confirms  the  intactness  of  the  drug in  the 
polymer matrix.
The TLC system used for this study is given below.
Pre-coated TLC Plates : Manufactured by SD Fine chemicals Ltd,
  Mumbai 
Adsorbent Layer : Silicagel GF254.
Layer Thickness : 250 µm.
Separation technique : Ascending 
Chamber Saturation : The chamber was lined on three sides with 
  filter paper and saturated for 30 minutes. 
Mobile phase : Chloroform : Methanol: Ammonia 
   (9 : 1 : .0.05)                             
66
Preparation of sample : A suitable amount of pure drug or 
   equivalent solid dispersion was dissolved 
   in ethanol and used for spotting
Amount applied : 10 µl 
Detection : Short and long wavelength of light 
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Fig 6
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Fig 7
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Fig 8
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Fig 9
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Fig 10
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Fig 11
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Fig 12
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FIG 13
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FORMULATION AND IN VITRO EVALUATION
Total 19 patches were prepared. In this the first 7 patches (F1 –
F7) contained the polymers CAB & PVP. The next 7 patches (F8-F14) 
were prepared using EC & HPMC in varying concentration. The last 5 
patches (F15-F19) prepared using EC& PVP. All the 19 patches were 
evaluated for physical appearance, moisture content, moisture uptake, 
weight  variation,  drug  content,  thickness  and  tensile  strength.The 
values are represented in table 6, 7 and 8.
Physical Appearance
The physical appearance for the patches F1-F7  was found to be 
transparent,  smooth  and  flexible.  The  next  patches  F8-F14  were 
translucent, moist and flexible. The last patches F15-F19  was found to 
be translucent, smooth and flexible. 
Moisture Content & Moisture Uptake
All the 19 patches (F1- F19) the percentage moisture content and 
moisture  uptake  was  found  to  increase  with  increase  in  the  PVP 
concentration. 
Weight variation
Out of  19  patches;  formulations  containing EC & HPMC in 
varying concentration showed an increase in weight compared to the 
other two batches containing CAB&PVP and EC& PVP.
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Drug content
Drug content in all the batches were found to be similar with 
minor  variations.  The  CAB-  PVP  patch  showed  maximum  drug 
content.
Film thickness 
Out of  19  patches;  formulations  containing EC & HPMC in 
varying concentration showed an increase in thickness compared to 
the other two batches containing CAB & PVP and EC & PVP.  
Tensile Strength 
The tensile Strength of CAB- PVP patches were found to be 
more when compared to EC - HPMC and EC - PVP Patches. 
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Table 6 Physico–chemical properties of the prepared transdermal patches of MT 
Patc
h no
Physical 
appearance
Percentage
Moisture 
content(±SD)
Percentage
Moisture 
uptake(±SD)
Weight 
variation in 
mg
(±SD)
Drug 
content in 
mg(±SD)
Film 
thickness in 
µg/cm2(±SD)
Tensile 
Strength 
in kg/ 
mm2
F1
Transparent, 
flexible and smooth 4.94±2.18 5.06±3.77 107.43±0.78 0.9838±0.8 0.138±1.44 1.81±3.27
F2
Transparent, 
flexible and smooth 5.39 ±2.71 6.65 ±5.14 110.62±0.33 0.9846±1.7 0.136±1.36 1.76±2.65
F3 Transparent, 
flexible and smooth 7.21 ±3.22 7.85 ±4.27 114.21±0.39 0.9896±0.6 0.132±2.24 1.28±3.69
F4
Transparent, 
flexible and smooth 8.52±3.81 8.74 ±2.84 117.33±0.72 1.0022±0.36 0.141±1.28 1.42±4.15
F5
Transparent, 
flexible and smooth 9.14 ±3.64 9.79 ±3.91 122.57±0.68 1.0080±1.1 0.135±2.12 1.69±2.41
F6
Transparent, 
flexible and smooth 9.52±5.24 10.23±4.81 124.12±0.82 1.018±0.22 0.138±1.45 1.34±1.15
F7
Transparent, 
flexible and smooth 10.11 ±5.19 11.47 ±3.21 127.45±0.42 1.030±0.52 0.134±1.54 1.53±2.67
n=5
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Table 7 Physico–chemical properties of the prepared transdermal patches of MT 
Patch 
no
Physical 
appearance
Percentage
Moisture 
content
(±SD)
Percentage
Moisture 
uptake
(±SD)
Weight 
variation in 
mg
(±SD)
Drug content 
in mg/cm2
(±SD)
Film 
thickness 
in µm
Tensile 
Strength 
in kg/ 
mm2
F8
Translucent, 
flexible, smooth. 3.91±1.14 4.11±2.71 117.14±0.22 0.9821±1.2 182±2.14 1.32±1.68
F9
Translucent, 
flexible, smooth. 5.37±2.37 5.35±1.77 121.37±0.24 0.9888±0.79 186±1.54 1.36±2.15
F10 Translucent, 
flexible, smooth. 6.91±3.27 7.05 ± 3.12 123.44±0.51 0.9924±0.48 179±2.6 1.04±3.39
F11
Translucent, 
flexible, smooth. 7.64±4.22 7.75 ±3.49 126.69±0.82 1.0031±0.52 184±1.58 1.12±2.42
F12
Translucent, 
flexible, smooth. 8.27±3.51 8.37±2.18 131.62±0.39 1.004±0.12 178±1.76 1.07±1.63
F13
Translucent, 
flexible, smooth. 8.64±2.54 9.25 ±2.19 134.58±0.71 1.015±1.82 181±1.42 1.18±3.71
F14
Translucent, 
flexible, smooth. 9.59±4.87 10.46±3.21 137.23±0.42 1.029±0.84 176±1.45 1.24±3.67
n=5 
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Table 8 Physico–chemical properties of the prepared  transdermal patches of MT 
Patch 
no
Physical 
appearance
Percentage
Moisture 
content
(±SD)
Percentage
Moisture 
uptake
(±SD)
Weight 
variation in 
mg(±SD)
Drug content 
in mg/cm2
(±SD)
Film 
thickness 
in µm
Tensile 
Strength  in 
kg/ mm2
F15
Translucent, 
flexible, 
smooth.
3.24±2.22 4.03±2.24 112.31±0.26 0.9084±1.32 152±1.22 1.13±2.14
F16
Translucent, 
flexible, 
smooth.
5.12±3.17 5.37± 3.32 114.98 ±0.34 0.9184±0.72 145±1.46 0.981±3.51
F17
Translucent, 
flexible, 
smooth.
6.29±4.24 6.88 ±3.56 119.27± 0.41 0.9260±0.39 157±2.12 0.996±2.69
F18
Translucent, 
flexible, 
smooth.
7.18±4.37 7.60±2.38 121.36 ±0.65 0.9762±0.72 153±1.68 0.957±1.59
F19
Translucent, 
flexible, 
smooth.
7.92±3.96 8.08 ±2.68 124.47 ±0.81 0.9829±0.54 148±2.24 0.923±3.73
n= 5 
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In vitro release
Formulations  F1-F7  containing  CAB-PVP  in  the  ratios 
9:1,8:2,7:3,  6:4,  5:5,  4:6  and  3:7  showed  a  steady  increase  in  the 
release with increase in time. Similarly formulations F8-F14 and F15  – 
F19   also showed a steady increase in release with time. Out of all the 
patches the patch containing CAB- PVP in the ratio 3:7 showed better 
release characteristics. The cumulative release of metoprolol tartrate 
released  from three  polymeric  films  in  24  hours  was  found  to  be 
between 42.9% to 49.2%.
Table 9 Cumulative percentage released for the patches F1, F8 and F15
Time
F1CAB-PVP 9:1 F8 EC- HPMC 9:1 F15 EC-PVP 9:1
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
1 15.61±3.64 1.586 12.45±4.68 1.259 10.52±4.38 1.158
2 44.33±2.46 4.505 37.57±3.35 3.83 16.54±4.29 1.820
3 74.27±2.95 7.549 47.91±4.87 4.98 26.22±5.92 2.886
4 91.57±5.23 9.307 71.37±3.11 7.267 49.79±3.12 5.481
5 117.61±4.35 11.95 96.18±2.41 9.79 69.54±2.82 7.655
6 142.13±3.27 14.44 112.45±3.55 11.449 87.36±1.98 9.616
7 161.87±4.48 16.45 132.39±5.82 13.48 107.54±4.76 11.838
8 183.38±3.18 18.639 148.73±2.55 15.144 132.67±4.14 14.604
9 199.78±4.13 20.306 174.92±3.71 17.810 162.45±3.29 17.883
10 211.62±4.77 21.510 198.33±4.79 20.194 195.49±2.13 21.499
24 441.32±2.95 44.85 419.74±3.47 42.73 381.12±2.16 41.955
n = 3
Fig 14
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Table 10 Cumulative percentage released for the patches F2, F9 and F16
Time
F2 CAB-PVP 8:2 F9 EC- HPMC 8:2 F16 EC-PVP 8:2
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
1 17.99±2.76 1.82 15.75±3.42 1.59 11.32±3.82 1.232
2 48.42±3.28 4.917 41.32±4.49 4.178 17.85±5.63 1.943
3 78.71±4.13 8.0 57.54±4.76 5.819 30.85±4.32 3.359
4 92.37±2.17 9.389 82.18±2.85 8.311 51.24±3.47 5.579
5 122.46±5.32 12.447 101.74±5.37 10.289 72.32±2.16 7.874
6 148.61±4.74 15.093 129.38±2.65 13.084 90.57±2.02 9.861
7 180.06±3.92 18.28 152.23±4.2 15.395 110.39±3.17 12.019
8 197.21±2.62 20.02 168.41±5.16 17.03 141.36±4.58 15.391
9 208.72±5.87 21.198 189.72±4.74 19.186 170.22±3.17 18.534
10 224.42±3.41 22.79 211.54±2.66 21.393 201.21±5.22 21.908
24 451.88±2.82 45.89 421.55±3.78 43.44 388.65±4.63 42.318
n = 3
Fig 15 
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Table 11 Cumulative percentage released for the patches F3, F10 and F17
Time
F3CAB-PVP 7:3 F10 EC- HPMC 7:3 F17 EC-PVP 7:3
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
1 20.07±5.14 2.028 18.38±3.87 1.852 11.49±2.76 1.240
2 51.24±2.75 5.177 45.75±4.66 4.610 23.37±4.42 2.523
3 81.37±4.37 8.222 61.27±3.44 6.173 31.39±2.17 3.387
4 96.27±3.92 9.728 88.45±3.67 8.912 53.27±4.35 5.752
5 129.54±5.78 13.090 105.83±2.57 10.664 78.92±2.45 8.517
6 156.32±3.46 15.79 137.94±5.43 13.899 92.45±3.28 9.983
7 183.24±4.17 18.516 166.78±3.71 16.805 113.37±3.92 12.242
8 202.57±2.55 20.46 182.42±2.48 18.381 146.57±4.74 15.828
9 214.62±3.42 21.687 198.17±3.29 19.968 173.25±3.76 19.122
10 236.47±4.68 23.89 217.45±2.76 21.911 205.61±5.42 22.204
24 463.97±2.64 46.884 432.62±5.62 43.89 392.64±4.17 42.401
n  = 3
Fig 16
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Table 12 Cumulative percentage released for the patches F4, F11 and F18
Time
F4CAB-PVP 6:4 F11 EC- HPMC 6:4 F18 EC-PVP 6:4
Cumulative 
amount released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
1 22.78±3.94 2.272 21.33±2.34 2.126 12.15±4.42 1.244
2 57.44±2.76 5.73 48.76±1.57 4.860 26.42±4.18 2.706
3 85.22±5.34 8.504 70.67±2.56 7.045 33.47±3.91 3.428
4 102.68±4.78 10.24 91.49±3.86 9.120 56.75±5.93 5.813
5 133.76±2.61 13.34 108.51±2.64 10.817 84.92±3.13 8.699
6 161.11±4.64 16.07 142.88±2.48 14.243 99.45±2.28 10.187
7 188.97±3.43 18.85 176.7±4.52 17.620 124.37±2.12 12.740
8 210.05±5.67 20.96 193.61±2.98 19.301 155.35±4.56 15.913
9 221.70±2.82 22.12 201.72±1.79 20.10 198.74±3.79 19.99
10 241.28±5.37 24.07 221.42±4.73 22.073 211.25±2.82 22.254
24 465.37±4.11 46.444 442.22±3.76 44.115 422.61±3.99 43.291
n = 3
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Table 13 Cumulative percentage released for the patches F5, F12 and F19
Time
F5CAB-PVP 5:5 F12 EC- HPMC 5:5 F19 EC-PVP 5:5
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount released 
µg/cm2(±SD)
Cumulative 
%  released
Cumulative 
amount 
released 
µg/cm2(±SD)
Cumulative 
%  released
1 23.34±4.76 2.315 21.14±3.98 2.132 14.91±3.31 1.518
2 61.76±2.25 6.12 56.21±4.47 5.598 29.32±5.17 2.983
3 91.74±3.66 9.101 76.42±2.56 7.611 42.37±4.18 4.310
4 109.04±5.16 10.81 97.61±2.34 9.722 61.62±2.87 6.269
5 138.42±4.63 13.73 110.32±4.77 10.988 87.37±4.38 8.889
6 166.95±4.58 16.56 156.31±5.64 15.568 101.45±4.41 10.321
7 193.31±2.97 19.17 188.31±2.73 18.755 132.57±5.92 13.487
8 216.77±3.72 21.50 198.12±4.11 19.733 161.82±3.79 16.463
9 226.51±5.69 22.47 205.32±3.69 20.699 201.22±2.57 20.472
10 248.52±2.18 24.65 226.31±2.44 22.540 201.22±2.57 22.537
24 477.25±2.89 47.34 449.751±5.61 44.751 431.25±4.91 43.875
n = 3
Fig 18
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Table 14 Cumulative percentage released for the patches F6 and F13
Time
F6CAB-PVP 4:6 F13 EC- HPMC 4:6
Cumulative amount 
released µg/cm2(±SD)
Cumulative  % 
released
Cumulative amount 
released µg/cm2(±SD)
Cumulative  % 
released
1 26.61±5.73 2.613 23.39±5.69 2.304
2 64.56±4.44 6.34 58.92±2.14 5.804
3 95.54±3.49 9.385 81.32±2.18 8.011
4 114.14±2.31 11.212 98.64±4.32 9.718
5 143.91±3.97 14.136 116.23±5.73 11.451
6 173.32±4.59 17.025 161.43±3.18 15.904
7 200.07±3.27 19.65 192.36±2.94 18.951
8 225.46±2.95 22.147 203.42±3.29 20.041
9 249.76±4.66 24.534 212.71±2.84 20.956
10 273.39±2.74 26.85 231.42±3.28 22.80
24 486.22±4.81 47.76 465.65±5.79 45.876
n=3
Fig: 19
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Table 15 Cumulative percentage released for the patches F7 and F14
Time
F7CAB-PVP 3:7 F14 EC- HPMC 3:7
Cumulative amount 
released µg/cm2(±SD)
Cumulative  % 
released
Cumulative amount 
released 
µg/cm2(±SD)
Cumulative  % 
released
1 27.73±2.67 2.692 24.17±5.19 2.348
2 67.37±4.94 6.540 60.31±3.32 5.861
3 97.39±2.48 9.455 83.45±4.72 8.109
4 121.42±3.26 11.788 102.37±2.91 9.948
5 147.39±4.44 14.369 118.15±4.32 11.477
6 178.61±3.53 17.340 174.27±4.38 16.935
7 201.09±3.14 20.105 196.51±2.6 19.097
8 229.59±5.61 22.290 212.76±5.68 20.619
9 253.39±3.85 24.600 219.81±3.36 21.362
10 281.42±5.39 27.322 235.24±4.37 22.861
24 507.39±4.74 49.26 476.22±3.91 46.279
n=3
Fig. 20
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STABILITY STUDIES
The  patches  F7,  F14  ,  F19   was  taken  for  accelerated  stability 
studies. By keeping it under 250C and 370C and observing the drug 
content and in vitro release for the interval of 10 days up to 30 days.  
Table 16 Percentage drug content for patches F7, F14 and F19 
during accelerated stability studies.
Time 
in 
days
Drug content (250c) Drug content (370 c)
F7 F14 F19 F7 F14 F19
0 100 100 100 100 100 100
10 100 100 100 99.70 99.61 99.91
20 99.92 99.87 99.96 99.51 99.42 99.89
30 99.67 99.63 99.81 99.22 99.03 99.78
Table 17 Cumulative percentage of drug release for patches F7, F14 and F19 during stability studies
Time
F7 CAB-PVP 3:7 F14 EC-HPMC 3:7 F19 EC-PVP 5:5
Cumulative 
amount 
released in 
mcg/cm2 (S.D)
Cumulative 
percentage 
released
Cumulative 
amount 
released in 
mcg/cm2 (S.D)
Cumulative 
percentage 
released
Cumulative 
amount 
released in 
mcg/cm2 (S.D)
Cumulative 
percentage 
released
1 26.29±1.34 2.57 23.24±3.15 2.280 12.26± 1.250±3.41
2 62.83±1.43 6.147 58.71±2.62 5.761 26.51± 2.703±2.79
3 96.54±3.21 9.446 80.42±2.47 7.892 40.76± 4.156±2.26
4 119.39±1.58 11.68 101.39±3.43 9.949 59.78± 6.095±1.72
5 142.47±2.36 13.94 116.24±1.38 11.407 86.54± 8.824±1.97
6 169.71±2.71 16.60 171.47±1.71 16.827 97.32± 9.923±2.38
7 199.76±1.19 19.545 194.51±3.54 19.088 131.68± 13.427±3.64
8 221.54±2.82 21.677 211.14±2.79 20.720 158.48± 16.159±2.89
9 247.24±3.47 24.191 230.28±2.23 22.598 197.51± 20.139±1.25
10 278.57±3.34 27.257 261.76±1.92 25.687 219.77± 23.409±2.84
24 495.39±1.64 48.47 465.34±2.19 45.663 417.68± 42.509±3.87
n = 3
Fig 21
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SUMMARY AND CONCLUSION
The  purpose  of  the  work  was  an  attempt  to  develop  a 
transdermal  drug delivery system of metoprolol  tartrate using three 
different polymer combinations i.e. CAB-PVP, EC- HPMC and EC- 
PVP in  different  ratios.  Total  of  19  patches  were  prepared  out  of 
which the CAB-PVP patches were found to have better characteristics 
than the other two patches.  
The compatibility  studies  confirmed  the  absence  of  chemical 
interaction  between the  drug and other  excipients  employed in  the 
formulation.  They  have  been  evaluated  for  physicochemical 
parameters  like  physical  appearance,  average  weight,  thickness, 
percent moisture content, percent moisture uptake and drug content. 
Release rates were found out by in vitro diffusion studies using Franz 
diffusion cell.
From the  in vitro release results observed, it was noticed that 
patches  prepared  using  CAB-PVP  proved  to  exhibit  better  release 
characteristics.  The  results  for  the  physicochemical  parameters  of 
CAB-  PVP  patches  were  also  better  than  the  other  two  patches 
containing EC- HPMC and EC- PVP.
Accelerated  stability  studies  indicated  that  the  formulated 
patches were having adequate shelf life.  The primary skin irritation 
studies  on rabbits  revealed that  the formulated  patch  is  compatible 
with skin.
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